Healthcare
Ipsen S.A.(IPSEY)
Live Price
Offline$43.85
+0.00% today
1Y Change
+50.95%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $13.81B
- Revenue Growth
- -1.2%
- EPS Growth
- +22.2%
- Dividend Yield
- 0.8%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ipsen S.A. (IPSEY) is a Healthcare stock with a market cap of $13.81B and listed on OTC. The stock last traded around $43.85 and up 50.9% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -1.2%, EPS growth of +22.2%, a dividend yield of 0.8%. What stands out right now is revenue -1.2%, EPS +22.2%, free cash flow +646.1% with operating margin 30.7% and ROIC 15.4%. The dividend is present but secondary, with a yield around 0.8%. Valuation already assumes a fairly strong business story at P/E 31.0 and price/sales 3.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IPSEY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.2% vs +7.6% peer median
Operating Margin
Above sector median
+30.7% vs +19.4% peer median
P/E
Below sector median
31.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 12, 2026 with an EPS surprise of +9.2% and a revenue surprise of +4.6%.
The operating picture looks softer than before
Revenue is at -1.2% and EPS is at +22.2%, with operating margin around 30.7%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 23, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 12, 2026 | +9.2% | +1.9% | +4.5% | -0.6% |
2025 Jun 30, 2025 | -27.6% | -0.5% | +2.5% | +7.3% |
2024 Dec 31, 2024 | โ | +0.0% | +3.3% | +13.6% |
Benchmark Edge
IPSEY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IPSEY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IPSEY Max Drawdown
-14.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IPSEY and SPY.
Company Overview
Ipsen S.A.
Other OTC
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
- Leadership
- David Loew
- IPO Date
- Aug 3, 2012
- Employees
- 5.4k
- Street Address
- 65 Quai Georges Gorse
- Mailing
- Boulogne-Billancourt, 92100
- Region
- Boulogne-Billancourt, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 58 33 50 00
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 31.0
- EV/EBITDA
- 12.1
- Price/Sales
- 3.8
- Price/Book
- 3.2
Growth
- Revenue
- -1.2%
- EPS
- +22.2%
- Free Cash Flow
- +646.1%
Profitability
- Gross Margin
- 70.6%
- Operating Margin
- 30.7%
- Net Margin
- 12.1%
- ROE
- 10.4%
- ROIC
- 15.4%
Balance Sheet
- Debt/Equity
- 0.24
- Current Ratio
- 1.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.